Tuesday, September 7, 2010

Stakeholder Opinions Hematopoietic Stem Cell Transplantation In need of further research and development

March 8, 2010 by biotechconnection.com · Leave a Comment 

Stakeholder Opinions Hematopoietic Stem Cell Transplantation In need of further research and development

Hematopoietic stem cell transplantation (HSCT) has evolved considerably over the past 50 years, driven by developments in stem cell sources, donor identification and conditioning regimens. Nowadays, it has a range of applications, including the treatment of certain hematologic malignancies. However, further research efforts are required to expand its use and improve patient outcomes.  ( http://www.bharatbook.com/detail.asp?id=98228&rt=Stakeholder-Opinions-Hematopoietic-Stem-Cell-Transplantation-In-need-of-further-research-and-development.html )

Scope

* Usage data for HSCT and overview of the procedure in terms of stem cell donors, stem cell sources, and conditioning regimens
* Discussion of the use of drug therapy in HSCT conditioning and in the management of complications, including current research and development trends
* Unmet needs and research priorities in the field of HSCT
* Stakeholder opinions based on qualitative interviews with key opinion leaders from the US and EU

Highlights

The use of HSCT has been increasing in the past decades, driven by developments in stem cell sources and conditioning regimens. However, it seems to remain an underutilized treatment, with many patients being referred for a transplant only at advanced stages of disease, where cure is less likely.

The development of reduced-intensity conditioning (RIC) regimens is one of the major advances in the field of HSCT. Current research evaluating monoclonal antibodies and radioimmunotherapy may help increase the efficacy and specificity of conditioning therapy.

The effective management of graft-versus-host disease (GVHD) is an unmet need in the field of HSCT. The availability of better preclinical models, prognostic tools, and effective therapies are considered R&D priorities. Monoclonal antibodies may have a role in the treatment of GVHD but further research is required to investigate their potential.

Reasons to Purchase

* Obtain analysis of current HSCT usage data and trends in the use of stem cell donors, stem cell sources, and conditioning regimens
* Obtain an overview of current drug use in HSCT conditioning and in the management of HSCT complications, including graft-versus-host disease
* Identify unmet needs and research priorities in the field of HSCT
 

To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=98228&rt=Stakeholder-Opinions-Hematopoietic-Stem-Cell-Transplantation-In-need-of-further-research-and-development.html

Or

Contact us at :

Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com
Follow us on twitter: http://twitter.com/3bbharatbook

We are the leading information aggregator, facilitates and supports the business information needs. With over 115,000 reports, you can get instant access and insights on the studies in yo for market research , corporate / strategic planning by providing the latest information in the form of reports, journals, magazines and databases on varied industries like automotive, oil and gas, shipping, textiles, pharmaceuticals, energy, banking, finance, insurance, risk management, country intelligence, consumer & durable goods, chemical and more ur areas of interest. Contact us at +91 22 27578668 / 27579438 or email info@bharatbook.com or our website www.bharatbook.com

Share and Enjoy:
  • Digg
  • del.icio.us
  • Facebook
  • NewsVine
  • Reddit
  • StumbleUpon
  • Google Bookmarks
  • Yahoo! Buzz
  • Twitter
  • Technorati
  • Live
  • LinkedIn
  • MySpace

Comments are closed.